Haemate P

Haemate P is a sterile solution containing human coagulation factor VIII and human von Willebrand factor, used as a coagulation factor replacement therapy. It is supplied without a specified strength or dosage form in the European market and is indicated for patients with hemophilia A and von Willebrand disease. The product provides exogenous clotting proteins to support normal hemostasis.

Haemate P is indicated for the management of bleeding episodes and perioperative prophylaxis in individuals with inherited deficiencies of factor VIII and von Willebrand factor. It is used in clinical practice to restore clotting activity and reduce bleeding risk.

- Treatment of acute bleeding episodes in hemophilia A patients. - Surgical and invasive procedure prophylaxis for hemophilia A. - Management of bleeding in von Willebrand disease types 1, 2, and 3. - Long‑term prophylaxis to prevent recurrent hemorrhage in severe hemophilia A. - Supportive therapy during childbirth for women with von Willebrand disease. - Adjunctive use when other factor concentrates are unavailable.

Adverse reactions to Haemate P may vary in frequency and severity. Common side effects are generally mild, while serious events are less frequent but require medical attention.

Common: - Headache - Fever or chills - Nausea or vomiting - Injection site erythema or swelling - Mild arthralgia - Transient increase in blood pressure

Serious: - Development of inhibitors (antibodies) against factor VIII or von Willebrand factor - Anaphylactic or severe allergic reactions - Thromboembolic events (e.g., deep vein thrombosis) - Hemolytic reactions - Severe hypertension or hypertensive crisis - Renal impairment associated with infusion.

Healthcare professionals should assess patient history and monitor for potential risks when using Haemate P. Specific considerations include:

- Screen for pre‑existing inhibitors to factor VIII or von Willebrand factor before initiating therapy. - Monitor for signs of allergic reactions, especially during the first infusion. - Use caution in patients with a history of thrombosis or cardiovascular disease. - Adjust dosing in patients with renal or hepatic impairment as clinically indicated. - Avoid use in individuals with known hypersensitivity to any component of the product. - Ensure proper storage conditions to maintain product stability. - Educate patients on recognizing symptoms of inhibitor development.

Haemate P may interact with other medications or substances that affect hemostasis or immune response. Consider the following when co‑administering:

Avoid: - Concurrent use of pro‑coagulant agents (e.g., activated prothrombin complex concentrates) without specialist guidance. - Administration with high‑dose aspirin or other non‑steroidal anti‑inflammatory drugs that increase bleeding risk.

Use with caution: - Immunosuppressive therapies that may alter inhibitor development. - Antifibrinolytic agents (e.g., tranexamic acid) – monitor for thrombotic complications. - Other plasma‑derived products – assess cumulative factor levels. - Vaccinations administered shortly before or after infusion – observe for enhanced immune response. - Herbal supplements affecting platelet function (e.g., ginkgo, garlic).